All In Biotech

Drug Trial Radar · NCT03784014

Molecular Profiling of Advanced Soft-tissue Sarcomas

Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

603

Actual

Start

Oct 19, 2019

Primary completion

Dec 1, 2023

Study completion Jan 20, 2026

Sponsor

Sponsor type
Government (non-federal)
Collaborators
Commissariat A L'energie Atomique; Institut Bergonié; Plateforme labellisée Inca - Institut Bergonié, Bordeaux; Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris; EUCLID Clinical Trial Platform
First posted
Dec 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MULTISARC is a randomized multicenter study assessing whether high throughput molecular analysis (next generation sequencing exome - NGS) is feasible in advanced/metastatic soft-tissue sarcoma patients, that is, whether NGS can be conducted for a large proportion of patients, with results available within reasonnable delays. In parallel, MULTISARC aims to assess efficacy of an innovative treatment strategy guided by high throughput molecular analysis (next generation sequencing exome, RNASeq \[NGS\]) in patients with Advanced/metastatic soft-tissue sarcomas. At the end of first-line treatment, participant's tumor profile of experimental Arm NGS (treatment strategy based on NGS results) will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant. Participants for whom a targetable genomic alteration has been identified will be proposed to enter in one of the subsequent phase II single-arm sub-trial.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • NilotinibDrug

    Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • CeritinibDrug

    Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • CapmatinibDrug

    Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • LapatinibDrug

    Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • TrametinibDrug

    Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • Trametinib and DabrafenibCombination product

    Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • Olaparib and DurvalumabCombination product

    Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • PalbociclibDrug

    Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • GlasdegibDrug

    Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.

  • TAS-120Drug

    Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.

  • Next Generation sequencing exomeOther

    Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the feasibility of high throughput molecular analysis (next generation sequencing exome [NGS]Time frame: 7 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Institut Bergonie

    Bordeaux, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut de Cancérologie de Montpellier

    Montpellier, France

  • Centre Antoine Lacassagne

    Nice, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Pitié Salpétrière

    Paris, France

  • Institut Curie

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Henri Becquerel

    Rouen, France

  • Institut de Cancérologie de l'Ouest - Site René Gauducheau

    Saint-Herblain, France

  • ICANS - Institut de Cancérologie Strasbourg

    Strasbourg, France

  • IUCT Oncopôle

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.